JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial
March 31, 2025 09:00 ET | Source: JenaValve Technology, Inc. IRVINE, Calif.…
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults…
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with…
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
March 24, 2025 16:05 ET | Source: Artiva Biotherapeutics, Inc. Initial data…
Optimus becomes the First Company to Conclude Study of Molnupiravir Phase 3 Clinical Trial with Promising Results
Optimus Group has announced the successful completion of the much-awaited Molnupiravir Oral…
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 20, 2025 17:35 ET | Source: vTv Therapeutics Inc. Clinical hold…
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Multi-center clinical trial includes sites located in the US, UK and EU…
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470…
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
March 17, 2025 08:00 ET | Source: CervoMed Inc. -Reported positive 16-week…
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer
March 15, 2025 11:25 ET | Source: ZENTALIS PHARMACEUTICALS Azenosertib median duration…